Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Persephin, a novel neurotrophic factor related to GDNF and neurturin.
Milbrandt J, de Sauvage FJ, Fahrner TJ, Baloh RH, Leitner ML, Tansey MG, Lampe PA, Heuckeroth RO, Kotzbauer PT, Simburger KS, Golden JP, Davies JA, Vejsada R, Kato AC, Hynes M, Sherman D, Nishimura M, Wang LC, Vandlen R, Moffat B, Klein RD, Poulsen K, Gray C, Garces A, Johnson EM Jr, et al. Milbrandt J, et al. Among authors: leitner ml. Neuron. 1998 Feb;20(2):245-53. doi: 10.1016/s0896-6273(00)80453-5. Neuron. 1998. PMID: 9491986 Free article.
Analysis of the retrograde transport of glial cell line-derived neurotrophic factor (GDNF), neurturin, and persephin suggests that in vivo signaling for the GDNF family is GFRalpha coreceptor-specific.
Leitner ML, Molliver DC, Osborne PA, Vejsada R, Golden JP, Lampe PA, Kato AC, Milbrandt J, Johnson EM Jr. Leitner ML, et al. J Neurosci. 1999 Nov 1;19(21):9322-31. doi: 10.1523/JNEUROSCI.19-21-09322.1999. J Neurosci. 1999. PMID: 10531437 Free PMC article.
PRO-ACTive sharing of clinical data.
Zach N, Leitner ML. Zach N, et al. Among authors: leitner ml. Nat Biotechnol. 2022 Jul;40(7):999-1000. doi: 10.1038/s41587-022-01395-y. Nat Biotechnol. 2022. PMID: 35778617 No abstract available.
Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach.
Kueffner R, Zach N, Bronfeld M, Norel R, Atassi N, Balagurusamy V, Di Camillo B, Chio A, Cudkowicz M, Dillenberger D, Garcia-Garcia J, Hardiman O, Hoff B, Knight J, Leitner ML, Li G, Mangravite L, Norman T, Wang L; ALS Stratification Consortium; Xiao J, Fang WC, Peng J, Yang C, Chang HJ, Stolovitzky G. Kueffner R, et al. Among authors: leitner ml. Sci Rep. 2019 Jan 24;9(1):690. doi: 10.1038/s41598-018-36873-4. Sci Rep. 2019. PMID: 30679616 Free PMC article.
Quantitative strength testing in ALS clinical trials.
Shefner JM, Liu D, Leitner ML, Schoenfeld D, Johns DR, Ferguson T, Cudkowicz M. Shefner JM, et al. Among authors: leitner ml. Neurology. 2016 Aug 9;87(6):617-24. doi: 10.1212/WNL.0000000000002941. Epub 2016 Jul 6. Neurology. 2016. PMID: 27385750 Free PMC article. Clinical Trial.
Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS?
Zach N, Ennist DL, Taylor AA, Alon H, Sherman A, Kueffner R, Walker J, Sinani E, Katsovskiy I, Cudkowicz M, Leitner ML. Zach N, et al. Among authors: leitner ml. Neurotherapeutics. 2015 Apr;12(2):417-23. doi: 10.1007/s13311-015-0336-z. Neurotherapeutics. 2015. PMID: 25613183 Free PMC article. Review.
16 results